SCHEMBL1995169

SCHEMBL1995169

O=C(OCCC(F)(F)F)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.63
LMNA P02545 2/20 0.59
MAPK1 P28482 2/20 0.56
HIF1A Q16665 1/20 0.56
SLC6A2 P23975 1/20 0.52
SLC6A3 Q01959 1/20 0.52
KMT2A Q03164 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
ALDH1A1 P00352 2/20 0.50
ESR1 P03372 1/20 0.47
ESR2 Q92731 1/20 0.47
TSHR P16473 2/20 0.47
F2 P00734 1/20 0.47
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
KDM4E B2RXH2 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13799195 0.93 TDP1 (0.56) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL28008710 0.89 TDP1 (0.70) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL26343108 0.86 TDP1 (0.59) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL21104459 0.86 LMNA (0.61) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL1993944 0.86 TDP1 (0.59) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL8351678 0.86 LMNA (0.61) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL1657037 0.84 TDP1 (0.58) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL3654393 0.83 TDP1 (0.41) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL8669408 0.83 LMNA (0.57) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL1995802 0.83 TDP1 (0.56) TDP1LMNAMAPK1HIF1ASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US claimed
CN-118756156-A Method for preparing deuterated cyclic compound 无锡绿能电合科技有限公司 2024-10-11 CN disclosed
US-10233191-B2 Fused piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-03-19 US disclosed
US-20160159815-A1 Fused Piperidine Amides as Modulators of Ion Channels VERTEX PHARMACEUTICALS INCORPORATED 2016-06-09 US disclosed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US disclosed
CN-101528713-B Pyridazine derivatives as inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 HOFFMANN LA ROCHE 2013-05-22 CN disclosed
EP-2338935-B1 FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF ASAHI GLASS CO LTD (JP) 2012-12-12 EP disclosed
US-20110172336-A1 FLUOROCOPOLYMER COMPOSITION AND ITS PRODUCTION PROCESS ASAHI GLASS COMPANY, LIMITED (JP) 2011-07-14 US disclosed
EP-2338935-A1 FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF ASAHI GLASS COMPANY, LIMITED (JP) 2011-06-29 EP disclosed
CN-101528713-A Pyridazine derivatives as inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 HOFFMANN LA ROCHE (CH) 2009-09-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10233191-B2 Fused piperidine amides as modulators of ion channels TRPV1, TRPA1, KCNJ2 TDP1 3900/4885LMNA 3728/4885MAPK1 3344/4885
US-20160159815-A1 Fused Piperidine Amides as Modulators of Ion Channels TRPV1, TRPA1, KCNJ2 TDP1 3900/4885LMNA 3728/4885MAPK1 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.